BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8774 related articles for article (PubMed ID: 33629336)

  • 21. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
    Gee J; Marquez P; Su J; Calvert GM; Liu R; Myers T; Nair N; Martin S; Clark T; Markowitz L; Lindsey N; Zhang B; Licata C; Jazwa A; Sotir M; Shimabukuro T
    MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(8):283-288. PubMed ID: 33630816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
    Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy.
    Parums DV
    Med Sci Monit; 2021 Sep; 27():e934625. PubMed ID: 34483336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson.
    Patel R; Kaki M; Potluri VS; Kahar P; Khanna D
    Hum Vaccin Immunother; 2022 Dec; 18(1):2002083. PubMed ID: 35130825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
    Eyre DW; Lumley SF; Wei J; Cox S; James T; Justice A; Jesuthasan G; O'Donnell D; Howarth A; Hatch SB; Marsden BD; Jones EY; Stuart DI; Ebner D; Hoosdally S; Crook DW; Peto TEA; Walker TM; Stoesser NE; Matthews PC; Pouwels KB; Walker AS; Jeffery K
    Clin Microbiol Infect; 2021 Oct; 27(10):1516.e7-1516.e14. PubMed ID: 34111577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
    Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
    Hause AM; Baggs J; Marquez P; Myers TR; Gee J; Su JR; Zhang B; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1755-1760. PubMed ID: 34968370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021.
    Wallace M; Woodworth KR; Gargano JW; Scobie HM; Blain AE; Moulia D; Chamberland M; Reisman N; Hadler SC; MacNeil JR; Campos-Outcalt D; Morgan RL; Daley MF; Romero JR; Talbot HK; Lee GM; Bell BP; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(20):749-752. PubMed ID: 34014913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
    Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
    Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
    Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021.
    Dooling K; Gargano JW; Moulia D; Wallace M; Rosenblum HG; Blain AE; Hadler SC; Plumb ID; Moline H; Gerstein J; Collins JP; Godfrey M; Campos-Outcalt D; Morgan RL; Brooks O; Talbot HK; Lee GM; Daley MF; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1344-1348. PubMed ID: 34555007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
    Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
    J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.
    Ostadgavahi AT; Booth R; Sisson G; McMullen N; Warhuus M; Robertson P; Miller M; Allen WC; El Sherif M; Brownlie R; Falzarano D; Richardson CD
    J Infect Dev Ctries; 2021 May; 15(5):653-656. PubMed ID: 34106888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers.
    Maruyama A; Sawa T; Teramukai S; Katoh N
    J Infect Chemother; 2022 Jul; 28(7):934-942. PubMed ID: 35361536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol.
    Patel GB; Chhiba KD; Chen MM; Guo A; Watts MM; Cullen J; Bochner BS; Grammer LC; Greenberger PA; Saltoun CA; Stevens WW; Kuang FL; Peters AT
    Allergy Asthma Proc; 2021 Nov; 42(6):515-521. PubMed ID: 34871159
    [No Abstract]   [Full Text] [Related]  

  • 36. [Comparative Analyses of IgA Antibody Response of Non-COVID-19 Infected People Over 60 Years Old Following CoronaVac and Pfizer-BioNTech COVID-19 Vaccination].
    Yürüker Ö; Yetkin O; Güvenir M
    Mikrobiyol Bul; 2023 Apr; 57(2):330-333. PubMed ID: 37067217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021.
    Hause AM; Baggs J; Gee J; Marquez P; Myers TR; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(39):1379-1384. PubMed ID: 34591835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021.
    Woodworth KR; Moulia D; Collins JP; Hadler SC; Jones JM; Reddy SC; Chamberland M; Campos-Outcalt D; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Mbaeyi S; Dooling K; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(45):1579-1583. PubMed ID: 34758012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
    Walsh EE; Frenck RW; Falsey AR; Kitchin N; Absalon J; Gurtman A; Lockhart S; Neuzil K; Mulligan MJ; Bailey R; Swanson KA; Li P; Koury K; Kalina W; Cooper D; Fontes-Garfias C; Shi PY; Türeci Ö; Tompkins KR; Lyke KE; Raabe V; Dormitzer PR; Jansen KU; Şahin U; Gruber WC
    N Engl J Med; 2020 Dec; 383(25):2439-2450. PubMed ID: 33053279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 439.